Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Unknown 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Prostatic Neoplasms 20Breast Neoplasms 7Salivary Gland Neoplasms 1Prostate Adenocarcinoma 1Neoplasms 1Neoadjuvant Therapy \ High Risk Prostate Cancer \ Docetaxel 1Drug-Related Side Effects and Adverse Reactions 1Bulbo-Spinal Atrophy, X-Linked 1Breast Cancer Invasive Nos 1Adenocarcinoma 1

Interventions

Triptorelin Pamoate 1Prednisone 1Docetaxel 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2 × Neoadjuvant Therapy \ High Risk Prostate Cancer \ Docetaxel × Triptorelin Pamoate × Clear all
NCT04869371 2022-12-29

Androgen Deprivation Therapy Combined With Docetaxel for High Risk Prostate Cancer

The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School

Phase 2 Unknown
75 enrolled
Genitourinary

Neoadjuvant Therapy \ High Risk Prostate Cancer \ Docetaxel

Data powered by HemOnc (CC BY 4.0) Colophon âš¡